Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
China Pharma Holding's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 4.26%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for China Pharma Holding's 3-Year ROIIC % or its related term are showing as below:
STU:XQJ's 3-Year ROIIC % is ranked better than 50.85% of 946
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs STU:XQJ: 4.26
China Pharma Holding (STU:XQJ) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
China Pharma Holding 3-Year ROIIC % Related Terms
China Pharma Holding 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for China Pharma Holding's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:XQJ vs TXMD, RMTI, AYTU: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, China Pharma Holding's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Pharma Holding 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Pharma Holding's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where China Pharma Holding's 3-Year ROIIC % falls into.
China Pharma Holding's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -2.638 (Dec. 2025) - -3.439 (Dec. 2022) )
/
( 29.429 (Dec. 2025) - 20.267 (Dec. 2022) )
=
0.801
/
9.162
=
8.74%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
China Pharma Holding (STU:XQJ) has a 3-Year ROIIC % of 4.26 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Pharma Holding and its competitors. According to the industry distribution chart, China Pharma Holding ranks #465 out of 946 companies in the Drug Manufacturers industry, placing it in the top 49.2%.
Is China Pharma Holding's 3-Year ROIIC % too high?
China Pharma Holding's current 3-Year ROIIC % is 4.26. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. China Pharma Holding's value of 4.26 is 14.5% above this industry median. Based on the distribution chart, China Pharma Holding ranks #465 out of 946 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Pharma Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's 3-Year ROIIC % compare to TXMD and RMTI?
According to the Drug Manufacturers industry distribution chart, China Pharma Holding ranks #465 out of 946 companies for 3-Year ROIIC %. This puts China Pharma Holding in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. China Pharma Holding's value of 4.26 is 14.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 946 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Pharma Holding's current 3-Year ROIIC % of 4.26 is 14.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on China Pharma Holding and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Pharma Holding's current 3-Year ROIIC % is 4.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current 3-Year ROIIC % of 4.26. The stock's GF Value™ is €0.79, compared to a current price of €26.80 — trading 3292.4% above its estimated fair value. The current 3-Year ROIIC % is 4.26 and 14.5% above the Drug Manufacturers industry median of 3.72. China Pharma Holding's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current 3-Year ROIIC % is 4.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Pharma Holding (STU:XQJ) Overvalued in 2026?
Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued.
The current stock price of €26.80 is trading 3292.4% above its estimated GF Value™ of €0.79.
Key valuation signals for STU:XQJ:
3-Year ROIIC %: 4.26
GF Value™: €0.79 vs. price of €26.80 (3292.4% above fair value)
Industry Position: 14.5% above the Drug Manufacturers median (#465 of 946)
No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score
Get the complete analysis for STU:XQJ
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:XQJ has been successfully added to your 
